Allergy immunotherapy teaches your immune system to stop overreacting by giving it the allergen in tiny, controlled doses — through the parts of your body best built to learn tolerance. The inside of your mouth is packed with immune cells that decide what’s safe. OLLEREG reaches all of them as a fine mist, not just the spot under your tongue like traditional drops.
“Most people think ‘sublingual’ means ‘just under the tongue.’ It doesn’t. The entire oral cavity — cheeks, gums, soft palate, tonsillar tissue — is packed with tolerance-inducing immune cells. OLLEREG was designed to reach all of it.”
— Dr. Dat Tran, MD, FAAAAI · Board-certified allergist/immunologist · Innovative Allergy, Houston TX
When you breathe in allergens, they don’t land in one place — they deposit across the lining of the mouth and throat, where distinct lymph node regions each play a role in teaching the immune system how to respond. Allergy drops deliver to a single sublingual spot. OLLEREG is Oromucosal Immunotherapy (OMIT): a spray-based delivery that mimics that natural exposure pattern, reaching the full oral mucosa and the lymph node regions that drain it. Below is the full science — how your immune system shifts over months from reacting to tolerating the allergen.
Traditional sublingual allergy drops reach one place: the sublingual mucosa, pooled under the tongue. OLLEREG’s patent-pending sublingual spray disperses a fine mist across the entire oral cavity — reaching five distinct tolerance-inducing immune regions in a single dose.
Thin non-keratinized epithelium. Dense Langerhans cells capture allergen within minutes. This is the only site reached by allergy drops — and the first of five that OLLEREG reaches.
Highly vascularized tissue rich in oral dendritic cells. The largest surface area in the mouth and a major site of tolerogenic antigen presentation. Drops never touch it.
Resident antigen-presenting cells with direct lymphatic drainage to the submandibular nodes — efficient immune education without passing through the gut, where allergen proteins are destroyed.
Waldeyer’s ring tissue — the tonsils and adenoids — evolved specifically to sample airborne antigens and decide what the immune system tolerates. A spray reaches this tissue; drops cannot.
Taste-bud-associated immune cells continuously sample the oral environment. Recent research implicates this tissue in oral tolerance specifically — a site of immune surveillance that spray coverage activates.
Why whole-mouth matters: The oral cavity is evolution’s tolerance organ. It has the lowest mast-cell density of any mucosal tissue, the highest density of regulatory T cells, and direct drainage to cervical lymph nodes — no gut degradation, no systemic exposure. Flooding the whole mouth is how you maximize the tolerance signal. Dr. Tran designed OLLEREG around this principle: the delivery method is the science.
Oral immunotherapy — also called Sublingual Immunotherapy (SLIT) when delivered under the tongue — is a medical approach that gradually desensitizes the immune system to specific allergens. Instead of avoiding allergens or masking symptoms with antihistamines, OIT addresses the underlying immune dysregulation: an immune system that over-responds to harmless proteins like pollen, pet dander, or dust mites.
The principle is simple, and the evidence is four decades deep: give the immune system the allergen in gradually increasing doses, in a place it’s designed to learn from, and the body stops attacking what used to trigger it. Same approach as allergy shots — delivered as a spray, at home, without needles.
What happens inside your body each time you use OLLEREG
When you spray OLLEREG under your tongue, the allergen proteins are absorbed through the sublingual mucosa — a thin, highly vascularized tissue. This region is uniquely rich in Langerhans cells and dendritic cells, which are antigen-presenting cells (APCs) that serve as the first line of immune recognition.
Dendritic cells capture the allergen and migrate to nearby lymph nodes, where they present allergen fragments to naive T-cells. Because the dose is tiny and the sublingual route favors tolerance, these T-cells are biased toward a regulatory phenotype rather than an allergic one.
In allergic individuals, the immune system produces high levels of IgE antibodies, which trigger mast cells to release histamine — causing sneezing, itching, and congestion. Over months of OIT, the immune system shifts: IgE production decreases while IgG4 — a "blocking" antibody — increases. IgG4 intercepts the allergen before it can bind to IgE, effectively neutralizing the allergic cascade.
Perhaps the most important change: OIT promotes the growth of regulatory T-cells (Tregs). Tregs produce anti-inflammatory cytokines (IL-10, TGF-beta) that suppress the Th2-driven allergic response. Over time, Tregs create a durable state of immune tolerance — your body genuinely learns that the allergen is not a threat. This is why the effects can last even after treatment ends.
Every category below has a role. The question is which mechanism is appropriate for long-term tolerance, and which just manages the symptoms.
The honest version: OLLEREG and clinic-based allergy shots are the only two treatments that actually rewire the immune response. Drops land in the same mechanism but reach one site of five. Antihistamines and homeopathics don’t change your biology — they change the experience. OLLEREG exists because the science supports a different answer than the one most patients have been given.
OLLEREG follows a carefully designed dose escalation schedule. Each month your spray contains a slightly higher concentration of allergen extract — gradually increasing the tolerance signal while staying well within the safe range documented across 30+ years of SLIT trials.
Maintenance dose is typically reached at approximately 6 months. Treatment continues at maintenance for a minimum of 3 years — the threshold the clinical literature associates with durable immune remodeling. Many patients continue to experience reduced symptoms years after completing treatment because the IgG4 / Treg tolerance signature is sustained.
OLLEREG also contains a patent-pending adjuvant that improves salivary absorption — the technology that makes whole-mouth dispersion a meaningful mechanism, not just a delivery preference. This formulation is unique to OLLEREG and developed by Dr. Dat Tran directly.
Sublingual immunotherapy has been studied continuously since the 1980s. Landmark Cochrane reviews (Radulovic 2010, Normansell 2015) analyzed over 4,500 patients and concluded SLIT significantly reduces symptom scores and rescue-medication use. The World Allergy Organization and the European Academy of Allergy and Clinical Immunology both endorse SLIT as a first-line treatment for allergic rhinitis, allergic asthma, and specific allergen sensitivities.
Clinical trials consistently show that approximately 80% of SLIT patients experience meaningful symptom reduction by the end of year one, with benefits compounding in years two and three. The sublingual route carries a significantly lower systemic-reaction risk than injection-based immunotherapy — most patients report only mild, transient oral itchiness during the initial weeks.
“I’ve seen this work in my own clinic for over a decade. The frustrating part was watching the technology stall at the drops stage — asking patients to hold liquid under their tongue for two minutes twice a day. OLLEREG is the delivery update that the mechanism always deserved. Same allergen science, designed around how the oral immune system actually works.”
— Dr. Dat Tran, MD, FAAAAI
Choose the spray that matches your allergies and start building tolerance today.
Shop Sprays